What is the cost of not treating MS with a disease modifying therapy?
- Lead researcher:
- Professor Ceri Phillips
- Based at:
- Swansea University and RAND Europe
- MS Society funding:
- £149,929
- Status:
- Complete
About the project
The cost effectiveness of disease modifying therapies (DMTs) is assessed before they are made available on the NHS. But these reviews don’t consider the wider benefits of DMTs, like helping people to stay in work for longer and reducing care requirements.
We want to understand the real cost of not treating MS for people with MS and their families, as well as the NHS.
Our researchers will review all the available data and work with people with MS to understand:
- the impact of relapses and progression on their quality of life
- their ability to work
- and the need for support from family members and other carers.
How will it help people with MS?
We can use this evidence to improve services for people with MS and to increase access to DMTs.
The difference you can make
You can help us to improve access to DMTs and support people with MS to make informed decisions about treatments.
You may also be interested in
The next research breakthrough is in reach
Your donation will help stop MS.
One-off donation
Monthly donation
